Alternatives to PepGLAD

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Automated cloud lab for protein validation — binding, expression and thermostability assays with data back in as little as 3 days

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

Matrubials is a UC Davis spin-off developing AI-identified antimicrobial peptides from mammalian milk, starting with a topical therapy for Bacterial Vaginosis.

Thesis is building Darwin, a humanoid robot for the home, with in-home deployment targeted for early 2027.

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Google's umbrella health initiative: consumer health info, research tools like AlphaFold, and clinical AI research.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.